Buch, Englisch, 378 Seiten, Format (B × H): 160 mm x 241 mm, Gewicht: 752 g
Reihe: Current Clinical Oncology
Buch, Englisch, 378 Seiten, Format (B × H): 160 mm x 241 mm, Gewicht: 752 g
Reihe: Current Clinical Oncology
ISBN: 978-1-61779-406-3
Verlag: Humana Press
Melanoma is an increasingly important public health problem. Although the cause of most malignant melanomas – over-exposure to ultraviolet light – is well known, effective treatment has remained challenging.
The past several years have been marked by extraordinary developments in melanoma treatment in the arena of targeted therapeutics. This book describes these ground-breaking discoveries and their implications for clinical use. As melanoma biology is increasingly understood, so the development of targeted therapies for this disease is spurred ahead. This book covers both established signal transduction inhibitors and the fascinating emerging realm of molecularly-guided immunotherapies.
This benchmark book provides the most up-to-date information on the new breed of melanoma therapies. Composed of the works of major researchers and clinicians, this book offers new insights, novel approaches, and promising data for effective treatment planning. Illuminating the latest advances in the field, it is a solid resource for clinical oncologists, translational scientists, and basic cancer researchers.
Zielgruppe
Research
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
Molecular targets and subtypes in melanoma.- Melanoma genomics.- Predictive biomarkers as a guide to future therapy selection in melanoma.- KIT as a therapeutic target for melanoma.- Targeted inhibition of B-Raf.- The notch and B-catenin pathways.- STAT3 and Src signaling in melanoma.- Targeting the mTOR, PI3K and AKT pathways in melanoma.- Targeting apoptotic pathways in melanoma.- Anti-angiogenesis therapy in melanoma.- Melanoma antigens recognized by T lymphocytes.- Melanoma vaccines.- Adoptive cell therapy for the treatment of metastatic melanoma.- Anti-CTLA-4 monolonal antibodies.- Anti-PD-1 and Anti-B7-H1/PD-L1 monoclonal antibodies.- Treatment of melanoma with agonist immune co-stimulatory agents.- Novel cytokines for immunotherapy of melanoma.- Modulating the tumor microenvironment.
